Board of Directors
Peter Friedli is a co-founder of Osiris and, except for the period between February and June 2004, has been a director since January 1996. Mr. Friedli has been a principal of the investment-banking firm Friedli Corporate Finance, Inc., since 1986. Friedli Corporate Finance, Inc., a leading Swiss venture capital firm, has made significant investments in the biotechnology industry. Friedli Corporate Finance, Inc., has been the primary source of financing for Osiris. Mr. Friedli is also President of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Prior to this, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. He also serves as a director in certain private companies. Mr. Friedli is also the largest single shareholder.
Thomas M. Brandt was elected to the Board of Directors in 2016. Mr. Brandt served as a board member for TeleCommunication Systems Inc. (TCS; NASDAQ:TSYS) from 2009 until its sale to Comtech Telecommunications in February, 2016, and was Chief Financial Officer for the company beginning in 1997. He led TCS through an IPO in 2000 and helped the company grow from $25 million of revenue in 1998 to nearly $400 million in 2015. Prior to TeleCommunication Systems, Mr. Brandt was CFO of Digex, Inc., an internet service provider, where he helped lead its 1996 IPO. Earlier in his career, he worked in the audit practice of Price Waterhouse for 12 years. Mr. Brandt currently serves as a member of the boards of Antenna Research Associates and the YMCA of Central Maryland, as well as on the Maryland Supplemental Retirement Plans Board. Mr. Brandt is a CPA with a bachelor’s degree in management science from Duke University and an MBA from the Wharton School of the University of Pennsylvania.
Thomas J. Knapp was elected to the Board of Directors in 2017. Mr. Knapp has over 25 years of corporate and large legal firm experience with regulated industries, with experience including Federal and State regulatory matters, Federal government affairs, risk management, compliance, litigation, complex commercial transactions, and corporate governance. Mr. Knapp is presently Interim General Counsel and Corporate Secretary with Galena Biopharma, Inc., prior to which his experience includes serving as EVP, Chief Legal Officer, and Corporate Secretary of Sucampo Pharmaceuticals, Inc., as Vice President, General Counsel and Corporate Secretary at NorthWestern Corporation, and in senior in-house attorney positions at The Boeing Company and The Burlington Northern & Santa Fe Railway Company.
Uwe Sommer was elected to the Board of Directors in 2017. Mr. Sommer is a highly experienced leader in global marketing and sales, managing distribution in markets including Europe, Japan, the Middle East, Africa, and the United States. Mr. Sommer has held executive roles with Johnson & Johnson, Lindt & Sprüngli, Mars, Inc., and Procter & Gamble. Mr. Sommer has degrees in Economics from University Kiel (Germany) and Marketing and Economics from Penn State University.
Mr. White has more than 25 years of corporate finance and public accounting experience with a track record of achievement in financial management, business and capital allocation strategy, and public company reporting, compliance and governance. Most recently, Mr. White served as Senior Vice President, Chief Financial Officer and Treasurer of Choice Hotels, a New York Stock Exchange listed company, from 2007 until 2016. Prior to joining Choice Hotels in 2002, Mr. White held positions with Ernst & Young, Arthur Andersen and Statoil Energy.